These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22329723)

  • 1. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
    Yan L; Shu-Ying Y; Shan K; Yip BH; Rong-Miao Z; Na W; Hai-Yan S
    Pharmacogenomics; 2012 Mar; 13(4):419-27. PubMed ID: 22329723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
    Li Y; Hu P; Cao Y; Wang GY; Wang N; Zhou RM
    Biomarkers; 2014 Mar; 19(2):128-34. PubMed ID: 24499239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
    Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
    Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    Krivak TC; Darcy KM; Tian C; Armstrong D; Baysal BE; Gallion H; Ambrosone CB; DeLoia JA;
    J Clin Oncol; 2008 Jul; 26(21):3598-606. PubMed ID: 18640939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
    Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
    Rubatt JM; Darcy KM; Tian C; Muggia F; Dhir R; Armstrong DK; Bookman MA; Niedernhofer LJ; Deloia J; Birrer M; Krivak TC
    Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
    Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
    Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
    Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
    Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
    Rulli E; Guffanti F; Caiola E; Ganzinelli M; Damia G; Garassino MC; Piva S; Ceppi L; Broggini M; Marabese M
    Sci Rep; 2016 Dec; 6():39217. PubMed ID: 27966655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
    Li Y; Zhang HL; Kang S; Zhou RM; Wang N
    Gynecol Oncol; 2017 Jan; 144(1):140-145. PubMed ID: 27836206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.
    Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL
    Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy.
    Biason P; Visentin M; Talamini R; Stopar A; Giorda G; Lucia E; Campagnutta E; Toffoli G
    Pharmacogenomics; 2012 Nov; 13(14):1609-19. PubMed ID: 23148637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer.
    Kang S; Ju W; Kim JW; Park NH; Song YS; Kim SC; Park SY; Kang SB; Lee HP
    Exp Mol Med; 2006 Jun; 38(3):320-4. PubMed ID: 16819291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
    Nikitas N; Karadimou A; Tsitoura E; Soupos N; Tsiatas M; Karavasilis V; Pectasides D; Pavlidis N; Chrisofos M; Adamakis I; Murray S; Fountzilas G; Dimopoulos MA; Bamias A
    Pharmacogenomics; 2012 Nov; 13(14):1595-607. PubMed ID: 23148636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
    Xu Q; Ding YY; Song LX; Xu JF
    Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.